# US 11,993,650 B2 · Pharmaceutical composition for treatment and prevention of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,650 B2
- Document ID: US11993650B2
- Status: Granted
- Kind: B2
- Application number: 16/800,852
- Filed: 2020-02-25
- Published: 2020-08-06
- Granted: 2024-05-28
- Earliest claimed: 2008-07-10
- Assignees: Toray Industries, Inc.
- Applicants: Toray Industries, Inc.
- Inventors: Fumiyoshi Okano; Takanori Saito; Takayoshi Ido; Masaki Shimizu
- Web page: https://patentgrep.com/patent/US11993650B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/3015: {Breast}
- C07K 16/3061: {Blood cells}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An antibody or a fragment thereof having immunoreactivity to a polypeptide comprising not less than 7 continuous amino acids in the CD179b protein, which was identified as a cancer antigen protein specifically expressed on the surfaces of cancer cells, can be used as a pharmaceutical composition for therapy and/or prophylaxis of cancer.

## Claims

### Claim 1

A method for therapy of human leukemia expressing CD179b protein comprising administering to a human patient having said leukemia an effective amount of an antibody, said antibody having immunoreactivity to a CD179b protein having the amino acid sequence shown in SEQ ID NO:3, wherein the antibody has an Fc effector domain capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) by effector cells and complement-dependent cytotoxicity (CDC) against CD179b-expressing cells sufficient to suppress or regress tumors in a living body, and wherein said leukemia is chronic lymphocyte leukemia, wherein said antibody comprises a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 105 and a light chain variable region having the amino acid sequence shown in SEQ ID NO: 109.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising administering a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said antibody is a human antibody, humanized antibody, chimeric antibody, single-chain antibody or bispecific antibody.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said antibody is a monoclonal antibody.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said antibody is conjugated to a cytotoxic moiety capable of inhibiting the proliferation and/or survival of the leukemia cells.